Cite
HARVARD Citation
Ettlin, R. et al. (n.d.). Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types. Toxicology letters. pp. S337-S338. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ettlin, R. et al. (n.d.). Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types. Toxicology letters. pp. S337-S338. [Online].